Jorn Gorlach
Algemeen Directeur bij AAvantgarde Laboratories AG
Profiel
Jorn Gorlach is the founder of Cogenics Icoria, Inc. (founded in 1997), Ercole Biotech, Inc. (founded in 2001), Arcanum Discovery, Inc. (founded in 2001), Montecito Bio Sciences Ltd.
(founded in 2006), and AAvantgarde Laboratories AG (founded in 2002).
At Cogenics Icoria, Inc., he held the title of Research Director in 1999.
At Ercole Biotech, Inc., he held the title of Director in 2003.
At AAvantgarde Laboratories AG, he is currently the Chief Executive Officer.
Dr. Gorlach's current job is as a Director at Parallax Diagnostics, Inc. Dr. Gorlach's former jobs included being a Director at Parallax Health Sciences, Inc. (2021-2022) and a Group Leader at Novartis, Inc. (1997).
Dr. Gorlach's education includes an undergraduate and graduate degree from the University of Hannover, a doctorate from the Swiss Federal Institute of Technology, and an MBA from Kenan-Flagler Business School (conferred in 2000).
Actieve functies van Jorn Gorlach
| Bedrijven | Functie | Begin |
|---|---|---|
Parallax Diagnostics, Inc.
 Parallax Diagnostics, Inc. Medical DistributorsDistribution Services Parallax Diagnostics, Inc. provides diagnostic testing systems and solutions. It develops bio-medical products, diagnostic and monitoring platforms in the area of infectious diseases. The company was founded on April 12, 2010 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | 22-04-2011 |
| AAvantgarde Laboratories AG | Algemeen Directeur | 01-01-2002 |
Eerdere bekende functies van Jorn Gorlach
| Bedrijven | Functie | Einde |
|---|---|---|
| PARX HEAL | Directeur/Bestuurslid | 25-03-2022 |
| PARX HEAL | Oprichter | 26-07-2017 |
Ercole Biotech, Inc.
 Ercole Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million. | Oprichter | 01-01-2003 |
Cogenics Icoria, Inc.
 Cogenics Icoria, Inc. Miscellaneous Commercial ServicesCommercial Services Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC. | Oprichter | 01-01-1999 |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Corporate Officer/Principal | 01-01-1997 |
Opleiding van Jorn Gorlach
| University of Hannover | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
| Kenan-Flagler Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Cogenics Icoria, Inc.
Cogenics Icoria, Inc. Miscellaneous Commercial ServicesCommercial Services Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC. | Commercial Services |
Parallax Health Sciences, Inc.
 Parallax Health Sciences, Inc. Packaged SoftwareTechnology Services Parallax Health Sciences, Inc. was an integrated digital healthcare company. It was engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operated through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offered a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment included the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consisted of management and administrative services. The company was founded on July 6, 2005 and was headquartered in Los Angeles, CA. | Technology Services |
Parallax Diagnostics, Inc.
Parallax Diagnostics, Inc. Medical DistributorsDistribution Services Parallax Diagnostics, Inc. provides diagnostic testing systems and solutions. It develops bio-medical products, diagnostic and monitoring platforms in the area of infectious diseases. The company was founded on April 12, 2010 and is headquartered in Cambridge, MA. | Distribution Services |
Ercole Biotech, Inc.
Ercole Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million. | Commercial Services |
| Montecito Bio Sciences Ltd. | |
| Arcanum Discovery, Inc. | |
| AAvantgarde Laboratories AG |